SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference, which takes place from August 5th through 8th.
Details for presentations related to GB001, an oral DP2 antagonist for eosinophilic asthma and chronic rhinosinusitis (CRS), are as follows:
Session Type: Thematic Poster Session Session Title: Asthma Clinical Trials (B31) Abstract Number: 3019 Poster Code: P378 Poster Title: Pharmacokinetics, Pharmacodynamics, and Safety of GB001 in Healthy Non-Asian, Non-Japanese Asian and Japanese Subjects Link: https://bit.ly/2P36tKx
Session Type: Thematic Poster Session Session Title: Asthma Subphenotypes, Targets and Therapeutics (D69) Abstract Number: 7417 Poster Number: P409 Poster Title: GB001 Is a Differentiated Potent Prostaglandin D2 Antagonist with Long Receptor Residence Time and Extended Pharmacodynamic Efficacy Link: https://bit.ly/2X6YZdR
Session Type: Thematic Poster Session Session Title: Asthma Epidemiology (D31) Abstract Number: 6478 Poster Number: P368 Poster Title: An Assessment of Asthma Control in a Real-World Setting Link: https://bit.ly/333BNBd
Details for a presentation related to GB002, an inhaled PDGFR inhibitor for pulmonary arterial hypertension (PAH), are as follows:
Session Type: Poster Discussion Session Session Title: Up-To-Date PAH Assessment and Management (B27) Abstract Number: 2907 Poster Number: P903 Poster Title: Phase 1a Randomized Double-Blind Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Studies of Orally Inhaled GB002 in Healthy Adult Subjects Link: https://bit.ly/3f7GqfT
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005335/en/
For Investors and Media: Bryan Giraudo, Chief Financial Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Source: Gossamer Bio, Inc.